NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the topical treatment and prevention of antibiotic-resistant infections, will issue a press release on Thursday, February 9, providing a business update regarding the Company’s progress during 2011 and its 2012 Outlook.
The release will be followed the same day by a conference call during which Dr. Ron Najafi, Chief Executive Officer, and Thomas Paulson, Chief Financial Officer, will discuss the Company’s year-end update and outlook. The conference call will begin at 10:00 a.m. (PDT) / 1:00 p.m. (EDT) and will be followed by a Q&A session. Participants calling in for the conference will dial 1-800-977-8002 (U.S. toll free) or 1-404-920-6650 (International); participant’s passcode: 271528#.
A live webcast will be available at http://www.wsw.com/webcast/cc/nby/. A replay of the webcast will be available shortly after the call.The replay may be accessed at http://www.novabaypharma.com/investors/events.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.
NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing NVC-422 Gel formulation for the highly contagious skin infection, impetigo. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the goal is to develop an eye drop for conjunctivitis. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections with an irrigation solution containing NVC-422. In hospital infections, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary anti-infective solution, NeutroPhase®, which has received two 510K clearances from the Food and Drug Administration. For additional information, visit: www.novabaypharma.com.
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson
Investors and Media:
The Ruth Group
Joshua Drumm, PhD (Investors)
Victoria Aguiar (Media)